Last reviewed · How we verify
CsA with steroid minimization
At a glance
| Generic name | CsA with steroid minimization |
|---|---|
| Also known as | Simulect; Dacortin; Sandimmun Neoral; Cellcept/Myfortic. |
| Sponsor | Armando Torres Ramírez |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients (PHASE3)
- Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (PHASE3)
- Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |